Cargando…

Risk of respiratory infection in patients with plaque psoriasis

Detalles Bibliográficos
Autores principales:	Svedbom, Axel, Mallbris, Lotus, Ståhle, Mona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the American Academy of Dermatology, Inc. 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955914/ https://www.ncbi.nlm.nih.gov/pubmed/33440215 http://dx.doi.org/10.1016/j.jaad.2020.12.083

Ejemplares similares

HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study
por: Mallbris, Lotus, et al.
Publicado: (2009)

Interleukin-17 and - 23 Inhibitors Associated with Direct Effects on Depressive Symptoms in Psoriasis: A Register Study
por: SVEDBOM, Axel, et al.
Publicado: (2023)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)

Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool
por: Leonardi, Craig, et al.
Publicado: (2021)

Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment
por: Boggs, Robert L, et al.
Publicado: (2014)

Cold stimulation test in patients with plaque psoriasis
por: Aleksiev, Teodor, et al.
Publicado: (2023)

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
por: Blauvelt, Andrew, et al.
Publicado: (2017)

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
por: Callis Duffin, Kristina, et al.
Publicado: (2019)

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA
por: Walsh, Jessica A, et al.
Publicado: (2018)

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
por: Blauvelt, Andrew, et al.
Publicado: (2018)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
por: Leonardi, Craig L., et al.
Publicado: (2022)

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study
por: Valenzuela, F., et al.
Publicado: (2016)

Risankizumab for Plaque and Guttate Psoriasis in a Patient with IgA-Related Glomerulonephritis
por: Dattola, Annunziata, et al.
Publicado: (2021)

Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis
por: Neema, Shekhar, et al.
Publicado: (2019)

A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
por: Armstrong, April W., et al.
Publicado: (2022)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Eruptive lentiginosis in resolving plaque psoriasis during treatment with risankizumab
por: Palmisano, Gerardo, et al.
Publicado: (2023)

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis
por: Griffiths, C.E.M., et al.
Publicado: (2016)

Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis
por: Cao, Zhiqiang, et al.
Publicado: (2022)

Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment
por: Gisondi, Paolo, et al.
Publicado: (2020)

Guselkumab for plaque psoriasis
Publicado: (2019)

Bimekizumab for plaque psoriasis
Publicado: (2022)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

The content validity of the PSS in patients with plaque psoriasis
por: Rentz, A. M., et al.
Publicado: (2017)

Stigmatization among Patients with Plaque Psoriasis
por: Jankowiak, Barbara, et al.
Publicado: (2023)

Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
por: Pettitt, Dan, et al.
Publicado: (2022)

Myocardial Infarction in a Patient Treated with Anti-Interleukin-12 Biological Agent for Chronic Plaque Psoriasis
por: Stinco, Giuseppe, et al.
Publicado: (2014)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
por: Gao, Jia C, et al.
Publicado: (2022)

Etanercept in the treatment of plaque psoriasis
por: Nguyen, Thao U, et al.
Publicado: (2009)

Infliximab for the treatment of plaque psoriasis
por: Gall, Jennifer S, et al.
Publicado: (2008)

Comments on the Risk of Gout in Patients with Psoriasis [Letter]
por: Yeh, Wen-Bin, et al.
Publicado: (2022)

A Response to: Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
por: Armstrong, April W., et al.
Publicado: (2022)

Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics
por: Ritchlin, Christopher T., et al.
Publicado: (2019)

Efficacy of Methotrexate in patients with plaque type psoriasis
por: Haider, Sabiqa, et al.
Publicado: (2014)

Prolidase activity in chronic plaque psoriasis patients
por: Sürücü, Hacer Altın, et al.
Publicado: (2015)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Evaluation of pancreatic function in patients with plaque psoriasis
por: Białecka, Agnieszka
Publicado: (2023)

Central Pain Sensitization in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2023)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
por: Malakouti, Mona, et al.
Publicado: (2016)

Prevalence of infection by Bartonella spp. in patients with psoriasis()()
por: Santos, Luciene Silva dos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4tlofdc1e69f3pr8lvqheokhk2